Premium
Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate
Author(s) -
Van Vliet H. A. A. M.,
Winkel T. A.,
Noort I.,
Rosing J.,
Rosendaal F. R.
Publication year - 2004
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/j.1538-7836.2004.00983.x
Subject(s) - cyproterone acetate , drospirenone , cyproterone , medicine , pharmacology , endocrinology , androgen , hormone
Oral contraceptives (OC) increase the risk of venous thrombosis through changes in procoagulant anticoagulant and fibrinolytic parameters. Thrombin generation-based activated protein C (APC) sensitivity is a global test for the net prothrombotic effect and predicts the risk of venous thrombosis. Recently concern has been raised about the thrombotic risk of a new OC composed of 3 mg drospirenone (DRSP) and 30 µg ethinylestradiol (Yasmin Schering AG Berlin Germany). Also a recent study showed a four-fold increased risk of thrombosis for users of OC containing cyproterone acetate (CPA) compared with users of OC containing levonorgestrel (LNG) and an 18-fold increased risk compared with non-users. (excerpt)